The incidence of malignant pleural mesothelioma is increasing. Untreated Because the entire ipsilateral pleural surface is at risk for involvement by diffuse malignant-pleural mesothelioma, the entire ipsilateral hemithorax is treated with radiation therapy (RT). The dose-limiting thoracic structures are the spinal cord (45 Gy), heart (45 Gy), and lung (20 Gy).22 Thus, safe thoracic radiation doses are below the 60-to 70-Gy doses thought to be necessary to control 3-cm masses of solid tumor.6 The smaller doses, however, may be effective in controlling microscopic disease after surgical debulking. Small series12,23 using RT as palliative single-modality therapy have reported symptomatic relief without a significant improvement in survival in patients receiving more than 40 Gy.
If RT is used as adjuvant therapy after debulking, 40 to 45 Gy should be delivered to the entire hemithorax, with a 5-to 5.5-Gy boost to areas at high risk for recurrence. When the lung is not included in the resection (as after pleurectomy), tangential fields need to be used to prevent severe radiation pneumonitis.6 When a pneumonectomy has been performed, a shift of the abdominal viscera into the inferior hemithorax may limit the safe dose to 30 Gy.
Chemotherapy
Single-agent doxorubicin has produced response rates of 0 to 40% in patients with malignant mesothelioma; similarly, response rates for chemotherapy combinations have only been 40% rized in Figure 1 . Although a toxic regimen, it offers the best chance of a long-term disease-free interval for a subgroup of patients.
Extrapleural pneumonectomy within this context is not meant as a curative procedure, but as a cytoreductive procedure. Its use in combination with two other modalities will, it is hoped, produce symptomatic relief, a long disease-free period, and possible cure for the individual patient. It entails the removal of the entire lung with its pleural envelope, along with the ipsilateral pericardium and diaphragm.
Patient Selection
Only patients with histologically proven mesothelioma and clinical evidence that the tumor is confined within the capsule of the parietal pleura are considered for extrapleural pneumonectomy. CT scan and chest MRI are used to determine the extent of intrathoracic and extrathoracic disease. The addition of MRI has aided in the preoperative evaluation of the extent of primary tumor. Chest MRI is particularly sensitive at detecting chest wall, mediastinal, and diaphragmatic invasion. Involvement of any of these structures or evidence of transdiaphragmatic extension has not been associated with any long-term survival. We consider patients with such involvement unlikely to benefit from extrapleural pneumonectomy and generally employ other forms of palliative therapy. The MRI graphically illustrates the thickened pleural peel, large pleural effusions, and imbrication of the trapped lung with subsequent shunting of deoxygenated blood. Sagittal MRI cuts are superior to conventional CT scan at evaluating possible invasion of the paravertebral sulcus, great vessels within the mediastinum, trachea, esophagus, and diaphragm.
If peritoneal invasion cannot be adequately ruled out prior to planned resection, an initial minilaparotomy or laparoscopy is used to evaluate the undersurface of the diaphragm. Biopsy specimen provedabdominal disease precludes thoracic resection.
Pulmonary function testing with dynamic spirometry, functional oximetry, and arterial blood gas measurement is obtained in patients being evaluated for surgery. A quantitative ventilation-perfusion scan is obtained if the initial FEV1 is less than 2 L or the predicted postoperative FEV1 is less than 1.2 L. Echocardiography will frequently detect mediastinal invasion, and preoperative ventricular function is a useful predictor of perioperative morbidity and mortality. It also provides a baseline standard against which to judge any future doxorubicin-induced cardiac toxic reactions. We repeat the echocardiography halfway through the postoperative chemotherapeutic regimen to detect any deterioration in cardiac function.
At our institution, patients with a predicted postoperative FEV1 of less than 1 L, an ejection fraction of less than 45% on echocardiogram, a room-air arterial carbon dioxide tension greater than 44 mm Hg, or oxygen tension less than 65 mm Hg receive palliative treatment without extrapleural pneumonectomy.
Mesothelioma is a locally aggressive disease that metastasizes very late in its clinical course. When metastases do occur, they are invariably accompanied by symptoms. Evaluation of occult distant metastases is unrewarding. Therefore, routine preoperative head CT scans and nuclear medicine bone scans are not indicated.
Operative Procedure
The technique of extrapleural pneumonectomy has been described in detail elsewhere.26'27 Briefly, it begins with a posterolateral thoracotomy incision over the sixth rib. The sixth rib is skeletonized of its surrounding periosteum and completely resected to provide wide exposure. Once the rib has been removed, the bed of the periosteum is incised and the pleura is stripped from the fifth and seventh ribs to begin the dissection. The pleural space is not deliberately entered. Particular attention is paid to achieving hemostasis because there is often diffuse bleeding from the chest wall after the pleura has been stripped away. Hemostasis is maintained by packing previously dissected areas of the operative field and through liberal use of the cautery in freshly dissected fields.
The margins of resection are limited by vital structures within the chest. The parietal pleura is bordered on three sides by the bony chest wall. The mediastinal border consists of the pericardium, great vessels, esophagus, trachea, and vertebral bodies.
The dissection is first completed anteriorly, from the apex to the diaphragm. As dissection approaches the apex, particular care is taken to preserve the subclavian vessels. In a similar fashion, the internal mammary artery and vein are carefully identified and preserved. Posteriorly, the azygous vein and superior vena cava are freed of their investing pleura on the right side. On the left side, the pleura is freed of the aorta. Involvement of the aorta may preclude resection.
Preserving the continuity of the pleural envelope necessitates resection of the diaphragm with the pleura. The peripheral margins of the diaphragm aredissected sharply until the underlying peritoneum is identified. The peritoneum is then dissected bluntly from the undersurface of the diaphragm with the assistance of a sponge stick.
The pericardium is then incised in front of the phrenic nerve. A flap of pericardium and the phrenic nerve are included in the specimen. The main pulmonary artery is divided with vascular staples, and the superior and inferior pulmonary veins are transected in a similar fashion. The pericardial resection is completed posterior to the hilum. The main stem bronchus is transected at the carina, generally with a stapler. The specimen is removed en bloc. Blood loss for pleuropneumonectomy is typically 500 to 750 mL.
The pericardium is repaired using a prosthetic patch after right-sided extrapleural pneumonectomies to prevent cardiac herniation. The patch is fenestrated with scissors after placement to prevent postoperative cardiac tamponade.
The bronchial staple line is reinforced with a vascularized pedicle or pericardial fat. If pericardial fat is not suitable, other options include vascularized intercostal muscle flaps or an omental flap brought up through the diaphragmatic defect prior to repair of the diaphragm.
The diaphragmatic defect is repaired with an impermeable prosthetic patch that prevents the displacement of abdominal contents into the empty hemithorax. Displacement of liver and bowel in the thorax may limit the dose of adjuvant radiotherapy that can be delivered to the posterior sulcus.
Analysis of the pathologic specimen explains much of the natural history of malignant pleural mesothelioma. The tumor generally has its primary focus at the base of the pleural space, where the heavy asbestos fibers accumulate. A markedly thickened peel extends over the entire surface of the lung and up into every fissure, and frequently invades the lung parenchyma. A decortication alone will leave islets of tumor within the lung. The pleural space is generally obliterated by the tumor at the site of the primary focus. The lung parenchyma is imbricated and trapped by the adherent peel along its surface. The volume of the lung is markedly reduced, and the red hepatization of the lung suggests marked shunting of deoxygenated blood. Sequential Adjuvant Chemotherapy and
Radiotherapy
The chemotherapeutic agents we use for adjuvant therapy after extrapleural pneumonectomy were known to have activity against mesothelioma at the time the protocol began in 1980. Table 26 summarizes the phase I trials evaluating the response of malignant pleural mesothelioma to doxorubicin-containing combinations.2528-33 The response rates ranged between 17 and 33%. The highest response rates were seen in therapy combining cisplatin with doxorubicin (29%)25,28 or cyclophosphamide and vincristine with doxorubicin (17 to 21%). [29] [30] [31] [32] [33] From 1980 to 1992, 52 selected patients at the Brigham and Women's Hospital received a trimodality protocol employing extrapleural pneumonectomy, adjuvant chemotherapy (cyclophosphamide, 600 mg/mi2; doxorubicin, 60 mg/mi2; and cisplatin, 70 mg/m2 for four to six cycles, to a cumulative doxorubicin dose of 450 mg/mi2), and 55 Gy adjuvant RT.'3 We used extrapleural pneumonectomy as cytoreductive surgery combined with aggressive systemic chemotherapy, followed by radical external radiation to the hemithorax. The lack of lung tissue in the diseased hemithorax allowed doses of 55 Gy to be given in this protocol.
Median age of selected patients was 53 years (range, 33 to 69 years). The conditions of all patients were clinically staged as Butchart stage I preoperatively (tumor confined to the ipsilateral pleural envelope). Thirty-two patients had the epithelial cell type, while 20 patients had the sarcomatoid or mixed-cell type. A history of asbestos exposure was elicited in 77% of patients.
Thirty-day mortality in this group was 5.8% (three deaths), with a 17% morbidity rate. The average hospital stay was 12 days.
As noted before, median survival for diffuse malignant mesothelioma without trimodality therapy ranges between 4 Even for those patients whose disease recurs, the palliation provided by extrapleural pneumonectomy is quite dramatic and cannot be appreciated by examining just the survival statistics. The clinical course of these patients is frequently a rapid and dramatic decline in function with progressive dyspnea, orthopnea, cachexia, and chest wall pain that is poorly controlled with narcotics. By eliminating the shunt fraction of the diseased lung, pneumonectomy can produce lasting palliation and local control for patients with recurrent disease.
The combination of several modalities seems to offer the best treatment for these patients. Our treatment plan continues to evolve. New protocols are being developed utilizing new chemotherapeutic agents and alterations in the timing of adjuvant RT. Furthermore, as experience with the protocol increases, the indications for operation are slowly expanding.
